HC Wainwright Boosts Earnings Estimates for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Investment analysts at HC Wainwright upped their FY2027 EPS estimates for Pharming Group in a note issued to investors on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now expects that the company will earn $0.54 per share for the year, up from their prior forecast of $0.50. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.22 per share.

Other equities research analysts have also issued reports about the company. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research report on Wednesday, September 23rd. Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Finally, Zacks Research cut shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Pharming Group currently has an average rating of “Hold” and a consensus target price of $38.67.

Pharming Group Trading Down 0.4%

PHAR opened at $9.95 on Friday. The firm has a market capitalization of $704.26 million, a price-to-earnings ratio of 82.92 and a beta of -0.04. The company’s 50 day simple moving average is $11.21 and its two-hundred day simple moving average is $13.30. Pharming Group has a 1-year low of $9.62 and a 1-year high of $21.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent SEC filing. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.